Travel-associated neurological disease terminated in a postmortem diagnosed atypical HSV-1 encephalitis after high-dose steroid therapy - a case report.
Autopsy
Brain
/ diagnostic imaging
DNA, Viral
/ blood
Encephalitis
/ diagnosis
Encephalitis, Herpes Simplex
/ diagnosis
Female
Gambia
Hashimoto Disease
/ diagnosis
Herpes Simplex
/ diagnosis
Herpesvirus 1, Human
/ genetics
Herpesvirus 2, Human
/ pathogenicity
Humans
Magnetic Resonance Imaging
Middle Aged
Retrospective Studies
Steroids
/ adverse effects
Travel
Encephalitis
Herpes simplex virus
Next generation sequencing
Steroid
The Gambia
Travel associated
Yellow fever vaccine associated neurological disease
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
18 Feb 2020
18 Feb 2020
Historique:
received:
13
12
2019
accepted:
06
02
2020
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
14
5
2020
Statut:
epublish
Résumé
Human encephalitis can originate from a variety of different aetiologies, of which infection is the most common one. The diagnostic work-up is specifically challenging in patients with travel history since a broader spectrum of unfamiliar additional infectious agents, e. g. tropical disease pathogens, needs to be considered. Here we present a case of encephalitis of unclear aetiology in a female traveller returning from Africa, who in addition developed an atypical herpes simplex virus (HSV) encephalitis in close temporal relation with high-dose steroid treatment. A previously healthy 48-year-old female presented with confusion syndrome and impaired vigilance which had developed during a six-day trip to The Gambia. The condition rapidly worsened to a comatose state. Extensive search for infectious agents including a variety of tropical disease pathogens was unsuccessful. As encephalitic signs persisted despite of calculated antimicrobial and antiviral therapy, high-dose corticosteroids were applied intravenously based on the working diagnosis of an autoimmune encephalitis. The treatment did, however, not improve the patient's condition. Four days later, bihemispheric signal amplification in the insular and frontobasal cortex was observed on magnetic resonance imaging (MRI). The intracranial pressure rapidly increased and could not be controlled by conservative treatment. The patient died due to tonsillar herniation 21 days after onset of symptoms. Histological examination of postmortem brain tissue demonstrated a generalized lymphocytic meningoencephalitis. Immunohistochemical reactions against HSV-1/2 indicated an atypical manifestation of herpesviral encephalitis in brain tissue. Moreover, HSV-1 DNA was detected by a next-generation sequencing (NGS) metagenomics approach. Retrospective analysis of cerebrospinal fluid (CSF) and serum samples revealed HSV-1 DNA only in specimens one day ante mortem. This case shows that standard high-dose steroid therapy can contribute to or possibly even trigger fulminant cerebral HSV reactivation in a critically ill patient. Thus, even if extensive laboratory diagnostics including wide-ranging search for infectious pathogens has been performed before and remained without results, continuous re-evaluation of potential differential diagnoses especially regarding opportunistic infections or reactivation of latent infections is of utmost importance, particularly if new symptoms occur.
Sections du résumé
BACKGROUND
BACKGROUND
Human encephalitis can originate from a variety of different aetiologies, of which infection is the most common one. The diagnostic work-up is specifically challenging in patients with travel history since a broader spectrum of unfamiliar additional infectious agents, e. g. tropical disease pathogens, needs to be considered. Here we present a case of encephalitis of unclear aetiology in a female traveller returning from Africa, who in addition developed an atypical herpes simplex virus (HSV) encephalitis in close temporal relation with high-dose steroid treatment.
CASE PRESENTATION
METHODS
A previously healthy 48-year-old female presented with confusion syndrome and impaired vigilance which had developed during a six-day trip to The Gambia. The condition rapidly worsened to a comatose state. Extensive search for infectious agents including a variety of tropical disease pathogens was unsuccessful. As encephalitic signs persisted despite of calculated antimicrobial and antiviral therapy, high-dose corticosteroids were applied intravenously based on the working diagnosis of an autoimmune encephalitis. The treatment did, however, not improve the patient's condition. Four days later, bihemispheric signal amplification in the insular and frontobasal cortex was observed on magnetic resonance imaging (MRI). The intracranial pressure rapidly increased and could not be controlled by conservative treatment. The patient died due to tonsillar herniation 21 days after onset of symptoms. Histological examination of postmortem brain tissue demonstrated a generalized lymphocytic meningoencephalitis. Immunohistochemical reactions against HSV-1/2 indicated an atypical manifestation of herpesviral encephalitis in brain tissue. Moreover, HSV-1 DNA was detected by a next-generation sequencing (NGS) metagenomics approach. Retrospective analysis of cerebrospinal fluid (CSF) and serum samples revealed HSV-1 DNA only in specimens one day ante mortem.
CONCLUSIONS
CONCLUSIONS
This case shows that standard high-dose steroid therapy can contribute to or possibly even trigger fulminant cerebral HSV reactivation in a critically ill patient. Thus, even if extensive laboratory diagnostics including wide-ranging search for infectious pathogens has been performed before and remained without results, continuous re-evaluation of potential differential diagnoses especially regarding opportunistic infections or reactivation of latent infections is of utmost importance, particularly if new symptoms occur.
Identifiants
pubmed: 32070282
doi: 10.1186/s12879-020-4859-5
pii: 10.1186/s12879-020-4859-5
pmc: PMC7029604
doi:
Substances chimiques
DNA, Viral
0
Steroids
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
150Références
Eur J Neurol. 2010 Aug;17(8):999-e57
pubmed: 20236175
MMWR Recomm Rep. 2010 Jul 30;59(RR-7):1-27
pubmed: 20671663
J Neurooncol. 2011 Nov;105(2):415-21
pubmed: 21637964
PLoS One. 2014 Apr 03;9(4):e93993
pubmed: 24699691
Vaccine. 2007 Feb 26;25(10):1727-34
pubmed: 17240001
Lung Cancer. 2007 Aug;57(2):243-6
pubmed: 17368625
Infection. 2019 Apr;47(2):267-273
pubmed: 30506479
J Virol Methods. 2015 Dec 15;226:1-6
pubmed: 26424618
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Curr Infect Dis Rep. 2017 Oct 3;19(11):45
pubmed: 28975470
Neurology. 2012 Nov 20;79(21):2125-32
pubmed: 23136265
J Neurovirol. 2016 Apr;22(2):240-5
pubmed: 26506841
N Engl J Med. 2014 Jul 3;371(1):68-73
pubmed: 24988560
Lancet Infect Dis. 2010 Dec;10(12):835-44
pubmed: 20952256
J Virol. 1992 Apr;66(4):2484-90
pubmed: 1312639
Pract Neurol. 2018 Oct;18(5):359-368
pubmed: 30042219
BMC Cancer. 2016 Mar 17;16:233
pubmed: 26988237
J Neurol. 2020 Jan;267(1):1-13
pubmed: 30536109
J Infect. 2018 Mar;76(3):225-240
pubmed: 29305150
Antiviral Res. 2006 Sep;71(2-3):141-8
pubmed: 16675036
Case Rep Oncol. 2014 Nov 21;7(3):774-9
pubmed: 25722668
Neurology. 2001 Apr 24;56(8):1114-5
pubmed: 11320194
Lancet. 2019 Feb 16;393(10172):702-716
pubmed: 30782344
Autoimmune Dis. 2014;2014:473170
pubmed: 25405025